The patent claims 2-amino-4-arylthiazole derivative compounds as inhibitors of the TRPA1 (transient receptor potential ankyrin, member 1) receptor. These compounds are potent antagonists on the basis of the results of in vitro assays, and are expected to be useful for treating conditions and disorders associated with TRPA1 function such as pain, chronic pain, neuropathic pain, rheumatoid arthritic pain, osteoarthritic pain, diabetic neuropathy and inflammatory disorders.
2-Amino-4-arylthiazole compounds as TRPA1 antagonists (WO 2012085662): a patent evaluation.
De Petrocellis L;
2013
Abstract
The patent claims 2-amino-4-arylthiazole derivative compounds as inhibitors of the TRPA1 (transient receptor potential ankyrin, member 1) receptor. These compounds are potent antagonists on the basis of the results of in vitro assays, and are expected to be useful for treating conditions and disorders associated with TRPA1 function such as pain, chronic pain, neuropathic pain, rheumatoid arthritic pain, osteoarthritic pain, diabetic neuropathy and inflammatory disorders.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
